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Several cytopathic mechanisms have been suggested to mediate
the dose-limiting cumulative and irreversible cardiomyopathy
caused by doxorubicin. Recent evidence indicates that oxidative
stress and mitochondrial dysfunction are key factors in the patho-
genic process. The objective of this investigation was to test the
hypothesis that carvedilol, a nonselective -adrenergic receptor
antagonist with potent antioxidant properties, protects against the
cardiac and hepatic mitochondrial bioenergetic dysfunction asso-
ciated with subchronic doxorubicin toxicity. Heart and liver mi-
tochondria were isolated from rats treated for 7 weeks with doxo-
rubicin (2 mg/kg sc/week), carvedilol (1 mg/kg ip/week), or the
combination of the two drugs. Heart mitochondria isolated from
doxorubicin-treated rats exhibited depressed rates for state 3 res-
piration (336  26 versus 425  53 natom O/min/mg protein) and
a lower respiratory control ratio (RCR) (4.3 0.6 versus 5.8 0.4)
compared with cardiac mitochondria isolated from saline-treated
rats. Mitochondrial calcium-loading capacity and the activity of
NADH-dehydrogenase were also suppressed in cardiac mitochon-
dria from doxorubicin-treated rats. Doxorubicin treatment also
caused a decrease in RCR for liver mitochondria (3.9  0.9 versus
5.6  0.7 for control rats) and inhibition of hepatic cytochrome
oxidase activity. Coadministration of carvedilol decreased the ex-
tent of cellular vacuolization in cardiac myocytes and prevented
the inhibitory effect of doxorubicin on mitochondrial respiration in
both heart and liver. Carvedilol also prevented the decrease in
mitochondrial Ca2 loading capacity and the inhibition of the
respiratory complexes of heart mitochondria caused by doxorubi-
cin. Carvedilol by itself did not affect any of the parameters
measured for heart or liver mitochondria. It is concluded that this
protection by carvedilol against both the structural and functional
cardiac tissue damage may afford significant clinical advantage in
minimizing the dose-limiting mitochondrial dysfunction and car-
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Doxorubicin (DXR; Adriamycin) is a potent and broad-
spectrum antineoplastic agent that is prescribed for the treat-
ment of a variety of cancers including leukemias and solid
tumors. The cytostatic effect of DXR is attributed to interca-
lation of the planar anthracycline ring structure into the double
helix of nuclear DNA to interfere with DNA replication and
transcription, especially in rapidly dividing cells. Unfortu-
nately, the therapeutic success is limited by the development of
a dose-dependent and irreversible cardiac toxicity that typically
presents as a dilated cardiomyopathy leading to congestive
heart failure (Lefrak et al., 1973). Because myocardial cells are
mitotically fixed, DXR cardiotoxicity is thought to be mani-
fested via mechanisms other than its cytostatic effect (Olson
and Mushlin, 1990; Singal et al., 1997; Singal and Iliskovic,
1998).
There is considerable evidence demonstrating that mito-
chondria are principal targets in the development of DXR-
induced cardiomyopathy (Olson and Mushlin, 1990; Singal et
al., 1997; Singal and Iliskovic, 1998). Cytofluorescence mi-
croscopy of heart tissue reveals nuclei and mitochondria as
exclusive sites of DXR localization (Nicolay et al., 1986) and
early stages of DXR cardiomyopathy are characterized by
changes in both the morphology and function of heart mito-
chondria (Ferrero et al., 1976; Mailer and Petering, 1976;
Bachmann and Zbinden, 1979; Bachmann et al., 1987), includ-
ing interference with mitochondrial calcium homeostasis at
subclinical cumulative doses (Solem and Wallace, 1993;
Solem et al., 1994; Zhou et al., 2000). There is growing
evidence that correlates the onset and severity of DXR cardio-
toxicity with disturbance in heart mitochondrial function and
bioenergetics (Mailer and Petering, 1976; Wallace et al.,
1997).
The biochemical mechanism underlying this mitochondrial
cardiotoxicity caused by DXR has not been fully elucidated.
The weight of evidence indicates that DXR cardiotoxicity is
mediated by oxygen free radicals (Olson et al., 1981; Powis,
1989; Olson and Mushlin, 1990; Singal et al., 1997, 2000;
Singal and Iliskovic, 1998) and that the mitochondrial inner
membrane is the primary site of free radical generation and
tissue damage (Doroshow, 1983; Davies and Doroshow, 1986;
Praet et al., 1988). Doxorubicin undergoes a futile redox cy-
cling on Complex I of the mitochondrial respiratory chain to
liberate highly reactive oxygen free radicals. Associated with
this is the oxidative modification of a specific calcium-con-
ducting channel leading to induction of the mitochondrial
permeability transition, interference with mitochondrial cal-
cium homeostasis, and the disruption of calcium-dependent
mitochondrial bioenergetics (Ferrero et al., 1976; Solem and
Wallace, 1993; Solem et al., 1994; Zhou et al., 2000). In view
of the implication of oxygen free radicals in the pathogenic
process, one of the approaches to minimize DXR cardiotoxic-
ity has been through the use of free radical scavengers and
other antioxidants (Praet et al., 1988; Siveski-Iliskovic et al.,
1995; Singal et al., 1997). However, these attempts have met
with mixed success.
Carvedilol (Kredex, Coreg) (1-[carbazolyl-(4)-oxy]-3-[(2-
methoxyphenoxyethyl) amino]-propanol-(2)), is a novel adren-
ergic antagonist that competitively blocks 1 and 2 vascular
receptors, primarily through a selective 1-blockade (Ruffolo
et al., 1991). The drug has been introduced for the treatment of
mild to moderate hypertension and has since been demon-
strated to benefit the management of several cardiomyopathies,
including ischemia-reperfusion and doxorubicin-induced car-
diomyopathy (Feuerstein et al., 1992, 1997; Matsui et al.,
1999). For example, carvedilol increases left ventricular ejec-
tion fraction with doxorubicin cardiomyopathy (Matsui et al.,
1999), but this may be more of a vascular effect than an effect
of carvedilol directly on the myocardium itself.
The mechanisms underlying this cardioprotective effect are
not fully understood. However, several reports suggest that
cardioprotection may be afforded through the potent antioxi-
dant activity of carvedilol, which is not shared by all -adren-
ergic antagonists (Feuerstein et al., 1992; Yue et al., 1992a,b;
Kramer and Weglicki, 1996; Tadolini and Franconi, 1998).
Carvedilol has been shown to scavenge oxygen free radicals
(Yue et al., 1994) and to inhibit lipid peroxidation in biological
systems (Yue et al., 1992a,b; Kramer and Weglicki, 1996).
Moreover, the antioxidant protection of carvedilol occurs
through a chain-breaking mechanism in postischemic rat hearts
(Kramer and Weglicki, 1996). The capacity of carvedilol to
inhibit lipid peroxidation is much greater than that of other
-adrenergic blocking agents, such as propranolol (Yue et al.,
1992a,b).
The purpose of this investigation was to assess the potential
cardioprotectant effect afforded by carvedilol against the free
radical-mediated cardiomyopathy and mitochondrial dysfunc-
tion that accompanies long-term treatment of rats with clini-
cally relevant cumulative doses of doxorubicin.
EXPERIMENTAL PROCEDURE
Chemicals. Reagents used in the experiments were as follows: tetraphe-
nylphosphonium chloride (TPPCl) (Aldrich Chemical Co., Milwaukee, WI);
ultrapure sucrose (ICN Biomedicals, Aurora, OH); calcium chloride, magne-
sium chloride (Fisher Scientific Company, Fair Lawn, NJ); potassium chloride
(EM Science, Gibbstown, NJ); potassium phosphate (J. T. Baker, Phillisburg,
NJ); arsenazo III (Calbiochem Corp., LaJolla, CA); cyclosporine A (CyA; a
generous gift from Sandoz Pharmaceutical Corp., East Hanover, NJ); protease
subtilopeptidase A type VIII, EGTA, HEPES, L-glutamic acid, and L-malic
acid (Sigma Chemical Company, St Louis, MO). Doxorubicin–HCl (adriamy-
cin) was purchased from Pharmacia & Upjohn (Milan, Italy). Carvedilol was
obtained from Boehringer Mannheim and used in DMSO solution. All reagents
were sodium free and reagent grade and were of the highest quality available.
Buffers were prepared using water passed through a Millipore Milli Q water
purification system (Millipore Corp., Bedford, MA) and the pH was adjusted
to pH 7.4 with KOH and HCl.
Animals. Adult male Sprague–Dawley rats, purchased from Harlan Spra-
gue–Dawley (Madison, WI) were maintained in a climate-controlled (21°C,
12-h light cycle), AAALAC-accredited animal care facility with free access to
food (Purina Rat Chow, Ralston Purina, Richmond, IN) and tap water. All
animals were allowed to acclimate for at least 5 days prior to the first injection.
Rats were divided randomly into four treatment groups of six animals each.
Each animal received seven weekly injections of doxorubicin (2 mg/kg sc),
carvedilol (1 mg/kg ip), or saline. Injection sites were rotated to minimize local
tissue irritation and injury. Rats were euthanized with CO2 followed by
decapitation in the 8th week (1 week after the last of seven weekly injections).
Preparation of heart and liver mitochondria. Heart and liver mitochon-
dria were prepared by conventional methods of differential centrifugation
(Solem and Wallace, 1993; Henry et al., 1995). The heart was immediately
excised and minced in ice-cold medium containing 250 mM sucrose, 1 mM
EGTA, and 5 mM Hepes–KOH, pH 7.4. The minced blood-free tissue was
rinsed and suspended in 5 ml of fresh medium and then homogenized with a
tightly fitted Potter–Elvehjen homogenizer and a Teflon pestle. Protease (1 mg
subtilopeptidase A type VIII prepared in 1 ml of isolation medium) was added
and the suspension was rehomogenized for an additional 30 s. The digested
homogenate was then immediately diluted with 30 ml medium followed by
another 30 s homogenization. The homogenate was divided into two 50-ml
tubes and centrifuged at 11,000g for 10 min at 4°C. The supernatant was
decanted and the pellet, devoid of protease, was gently homogenized to its
original volume with isolation medium and a loose-fitting homogenizer. The
suspension was centrifuged at 900g for 10 min and the low-speed supernatant
was filtered through two layers of cheesecloth and then centrifuged at 9000g
for 10 min to pellet the mitochondrial membranes. The high-speed supernatant
was discarded and the pellet was gently resuspended and repelleted at 9000g
for 10 min. EGTA was omitted from the final washing medium. The final
mitochondrial pellet was resuspended in isolation medium (without EGTA) at
a final concentration of 20–40 mg protein/ml.
Liver was excised and minced in an ice-cold isolation medium containing
250 mM sucrose, 1 mM EGTA, and 5 mM Hepes–KOH, pH 7.4. The minced
tissue was rinsed twice with isolation medium to remove blood and other
debris. The tissue was then homogenized with a tightly fitted Potter–Elvehjen
homogenizer and centrifuged at 900g for 10 min. The low-speed supernatant
was transferred to new centrifuge tubes and subjected to centrifugation at
9000g for 10 min. The mitochondrial pellet was washed once and resuspended
in isolation medium (without EGTA) to a final concentration of 60–80 mg
protein/ml.
All isolation procedures were performed at 0–4°C. The mitochondrial
suspensions were used within 4 (heart mitochondria) or 6 h (liver mitochon-
dria). Mitochondrial suspensions were maintained on ice (0–4°C) throughout
this period. Isolation procedures yielded well-coupled mitochondria: the respi-
ratory control ratio (RCR) of the isolated mitochondria varied from five to
eight (with malate-glutamate as substrate) or three to four (with succinate as
substrate), as determined according to the method of Estabrook (1967). Mito-
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chondrial protein was estimated according to the Bradford method (Bradford,
1976) using bovine serum albumin as standard.
Oxygen consumption assays. Oxygen consumption was measured polaro-
graphically, at 25°C, using a YSI Biological Oxygen Monitor (Model 530,
Yellow Springs Instrument, Yellow Springs, OH) and a Clark-type oxygen
electrode connected to a chart recorder (Kipp & Zonen, model BD 112).
Reactions were conducted in a 1-ml closed thermostatted and magnetically
stirred glass vessel containing 0.5 mg of mitochondrial protein in a respiration
buffer of 130 mM sucrose, 50 mM KCl, 2.5 mM KH2PO4, and 5 mM Hepes,
pH 7.4. After a 1-min equilibration period, mitochondrial respiration was
initiated by adding glutamate and malate to a final concentration of 1 mM each.
State 3 respiration was measured after adding 0.25 mM ADP; state 4 was
measured as the rate of oxygen consumption in the absence of ADP. The RCR
(state 3/state 4 rate) and the ADP/O ratio were calculated as described by
Estabrook (1967), using 474 ngatom O/ml as the value for the solubility of
oxygen at 25°C in doubly distilled water (Kamo et al., 1979). The concentra-
tion of the stock solution of ADP was confirmed spectrophotometrically at 260
nm using a molecular extinction coefficient of 16 cm1M1.
Mitochondrial membrane potential measurements. Mitochondrial mem-
brane potential () was estimated by monitoring the accumulation and
release of the lipophilic cation tetraphenylphosphonium (TPP) with a TPP-
sensitive electrode prepared according to the procedure described by Kamo
(Kamo et al., 1979). A minielectrode was constructed with a poly(vinyl
chloride) tube sealed with a poly(vinyl chloride)-based membrane containing
tetraphenylboron as a cation exchanger and filled with a 10-mM TPP solu-
tion. The reference electrode was an Ag/AgCl-saturated electrode. Both the
TPP electrode and the reference electrodes were connected to a pH meter and
inserted into a thermostatted glass chamber. The signals were fed to a dual-
trace potentiometric recorder (Kipp & Zonen, model BD 112). Mitochondria
were incubated in the reaction medium (130 mM sucrose, 50 mM KCl, 2.5 mM
KH2PO4, and 5 mM Hepes, pH 7.4) supplemented with 1 M TPP. This
TPP concentration was chosen to achieve high sensitivity and to avoid
possible toxic effects on mitochondria. The transmembrane electric potential
was estimated from the following equation (at 25°C) assuming that the distri-
bution of TPP between mitochondria and the medium follows the Nernst
equation, as previously described:
mV  59 logv/V  59 log10 E/59  1) ,
where v, V, and E represent mitochondrial volume, volume of the incubation
medium, and the deflection of the electrode potential from the baseline,
respectively. No correction was made for the “passive” binding contribution of
TPP to the mitochondrial membranes because the purpose of the experiments
was to show relative changes in potential rather than absolute values. When
necessary, the electrode membrane was washed with a suspension of protein to
remove hydrophobic reagents and maintain the response time and sensitivity to
TPP. Calculations of the transmembrane potential were based on a mitochon-
drial matrix volume of 1.1 l/mg protein.
Measurement of calcium transport by mitochondria: Ca2 loading ca-
pacity. The Ca2-loading capacity of mitochondria was estimated spectro-
photometrically at 660 nm in a Beckman DU-7400 spectrophotometer, accord-
ing to previously published procedures (Solem and Wallace, 1993; Zhou et al.,
2000). The assay medium (130 mM sucrose, 50 mM KCl, 2.5 mM KH2PO4,
and 5 mM Hepes, pH 7.4) was supplemented with 100 M Arsenazo III, 2 M
rotenone, and 1 g/ml oligomycin. Mitochondria were suspended at 0.25
mg/ml in 2 ml of medium added to a cuvette maintained at 25°C. After 1 min
of incubation, Ca2 was added (40 nmol for liver mitochondria and 200 nmol
for heart mitochondria), and mitochondria were energized with 10 mM succi-
nate. Where indicated, cyclosporin A and carvedilol were added just before
adding CaCl2. None of these reagents interfere with the spectrophotometric
analysis.
Enzyme assays. All assays were performed at 25°C, with a Beckman DU
7400 spectrophotometer. The activities of complexes I and IV were measured
as described by Birch-Machin and collaborators (Taylor et al., 1993) with
slight modifications. Mitochondrial samples were subjected to three cycles of
fast freeze–thaw in hypotonic buffer (20 mM potassium phosphate buffer, pH
7.2) before the enzymatic assays. NADH dehydrogenase was quantitated by
the rate of NADH oxidation followed at 340 nm. The NADH:ubiquinone
oxidoreductase (Complex I) assay medium contained 25 mM potassium phos-
phate buffer, pH 7.2, 5 mM MgCl2, 2.5 mg/ml bovine serum albumin (fraction
V), 0.13 mM NADH, and 65 M decylubiquinone, a soluble short-chain
analogue of ubiquinone, and supplemented with 2 g/ml antimycin A and 2
mM potassium cyanide to block electron transport downstream from Complex
I. After 1 min, 0.25 mg mitochondria was added to initiate the reaction and the
initial rate of NADH oxidation was monitored at 340 nm (  6.81
mM1cm1) for 1 min. Complex I activity was inhibited by 2 g/mL of
rotenone. Complex IV specific activity was determined as the rate of oxidation
of reduced cytochrome c at 550 nm. Ferrocytochrome c was prepared by
reducing ferricytochrome c with excess sodium dithionite, followed by Seph-
adex G-25 chromatography to remove unreacted Na2SO4 (Trounce et al.,
1996). The reaction mixture consisting of 20 mM potassium phosphate buffer,
pH 7.0, 0.45 mM n-dodecyl--D-maltoside, and 15 M ferrocytochrome c was
incubated at 25°C for 1 min, and mitochondria (10 g protein) was added to
initiate the reaction. The reaction was first order with respect to cytochrome c.
The pseudo first-order rate constant was calculated and the results are pre-
sented as (min/mg)1 of protein.
Statistical analysis. Results are presented as the mean  SEM for the
number of experiments indicated in the legends to the figures. Statistical
evaluation was performed using the two-tailed Student’s t test; differences with
a value of p 	 0.05 were considered significant.
Light and electron microscopy. Small blocks of cardiac muscle from the
midportion of the lateral wall of the left ventricle were fixed in 2.5% glutar-
aldehyde–2% formaldehyde in 0.1 M phosphate buffer, pH 7.4, postfixed in
1% OsO4 in the same buffer, dehydrated in graded acetone solutions, and
embedded in epon-araldite. One-micrometer-thick sections for light micros-
copy were stained with 0.25% toluidine blue in 1% sodium borate (Zhou et al.,
2000). Thin sections for electron microscopy were stained with lead citrate and
uranyl acetate.
Tissue examination. The heart tissue was examined for histopathological
evidence of cardiomyopathy according to the 0–3 scoring method of Billing-
ham et al. (1978) and Bristow et al. (1981); see also Zhou et al. (2000) using
coded slides and electron microscopy grids: grade 0, no change from normal;
grade 1, limited number of isolated cells (less than 5% of total number of cells
per block) exhibiting early myofibrillar loss and/or cytoplasmic vacuolation;
grade 2, groups of cells (5 to 30% of total number) exhibiting marked
myofibrillar loss and/or cytoplasmic vacuolization; and grade 3, diffuse cell
damage (
30% of total number) with the majority of cells exhibiting marked
loss of contractile elements, loss of organelles, and mitochondrial and nuclear
degeneration. In addition, damaged cardiomyocytes in a 202,500-m2 total
cross-sectional region of ventricular wall were counted with the aid of an
eyepiece grid and light microscope. These counts were used to compute the
mean number of myocytes that were damaged per unit area, resulting in the
“cell damage score” reported in Table 6. All slides were scored independently
by two examiners, both of whom were blinded to the tissue sample code.
RESULTS
Body, Heart, and Liver Weight
Rats received seven weekly injections of saline, DMSO,
doxorubicin (2 mg/kg sc) and/or carvedilol (1 mg/kg ip) and
then were killed 1 week following the last injection. All of the
animals survived the entire 8-week treatment. However, DXR-
treated rats weighed 10–15% less compared to control rats
(Table 1). The lower body weight was significant despite
obvious thoracic and abdominal ascites, which was not re-
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versed by concomitant treatment with carvedilol. Heart weight
was also lower in DXR-treated rats, with or without concom-
itant carvedilol treatment (Table 1). However, heart/body
weight ratio was not altered by any combination of drug
treatments. The liver of DXR-treated rats was congested and
enlarged due to the ascites, which was not prevented by carve-
dilol.
Respiration and Oxidative Phosphorylation of Isolated
Mitochondria
The effects of the different drug treatments on state 3 and
state 4 respiration, RCR, and coupling of oxidative phosphor-
ylation (ADP/O ratio) of heart and liver mitochondria are
presented in Tables 2 and 3, respectively. Chronic DXR ad-
ministration resulted in compromised respiratory function of
cardiac mitochondria (Table 2). Following DXR treatment,
state 3 respiration rate was decreased 20% compared with
control (336  26 versus 425  53, p 	 0.05), whereas state
4 respiration was not altered. Consequently, the RCR of car-
diac mitochondria from DXR-treated rats was significantly
(25%) lower compared to controls (4.3  0.6 and 5.8  0.4,
respectively, p 	 0.05). However, the efficiency of ATP
synthesis as indicated by ADP/O ratio for cardiac mitochondria
was not impaired following DXR treatment. Carvedilol treat-
ment by itself did not alter any of the parameters of mitochon-
drial respiration. However, when coadministered with DXR,
carvedilol prevented the DXR-induced inhibition of state 3
respiration rate and restored the RCR of cardiac mitochondria
to control values (Table 2).
The effects of DXR and carvedilol treatment of liver mito-
chondria are summarized in Table 3. Although neither drug
treatment altered either state 3 or state 4 respiration by liver
mitochondria, DXR did cause a significant inhibition of RCR,
which was prevented by the coadministration of carvedilol
(3.9 0.9 versus 5.4 0.8, respectively). As was observed for
heart, the ADP/O ratio for liver mitochondria was not altered
by DXR treatment. Carvedilol by itself did not affect any of the
studied mitochondrial respiratory parameters from either liver
or heart mitochondria (Tables 2 and 3).
TABLE 1
Rat Body, Heart, and Liver Weights
Treatment
Body weight
(g)
Heart weight
(g)
Liver weight
(g)
Heart/body ratio
(103)
Liver/body ratio
(103)
Saline 372  15 1.2  0.05 13.5  0.7 3.2  0.003 36  0.05
Doxorubicin 325  30* 0.97  0.09* 18.4  1.8* 3.0  0.003 57  0.06*
Carvedilol 371  18 1.23  0.08 13.9  1.1 3.3  0.004 37  0.06
Doxorubicin  carvedilol 330  27* 1.0  0.06* 16.8  0.9* 3.3  0.002 51  0.03†
Note. Values are means  SEM (n  6) for animals receiving seven weekly injections of doxorubicin 2 mg/kg/week sc and carvedilol 1 mg/kg/week ip.
* Statistically significant compared to control group (p 	 0.05).
† Statistically significant compared to doxorubicin group (p 	 0.05).
TABLE 2
Effects of Doxorubicin Treatment on Oxidative Phosphorylation
in Rat Heart Mitochondria
Treatment
Respiration rate (natoms O/min/mg protein)
State 3 State 4 RCR ADP/O
Saline 425  53 74  11 5.8  0.4 2.7  0.2
Doxorubicin 336  26* 79  11 4.3  0.6* 3.0  0.2
Carvedilol 417  55 72  8 5.8  0.5 2.6  0.3
Doxorubicin  carvedilol 418  62† 70  13 6.0  0.5† 2.7  0.2
Note. Data represent the means  SEM for cardiac mitochondria isolated
from six individual rats receiving weekly injections for 7 consecutive weeks.
Oxidative phosphorylation was measured polarographically at 25°C in a total
volume of 1 ml. Respiration medium and other experimental details are given
under Experimental Procedure. State 3 and state 4 respiration rates, RCR, and
ADP/O were calculated as described under Experimental Procedure.
* p 	 0.05 compared to control.
† p 	 0.05 compared to doxorubicin-treated rats.
TABLE 3
Effects of Doxorubicin Treatment on Oxidative Phosphorylation
in Rat Liver Mitochondria
Treatment
Respiration rate (natoms O/min/mg protein)
State 3 State 4 RCR ADP/O
Saline 111  20 20  3 5.6  0.7 2.6  0.3
Doxorubicin 90  18 24  4 3.9  0.9* 2.8  0.4
Carvedilol 115  17 22  2 5.3  0.7 2.5  0.3
Doxorubicin  carvedilol 101  28 18  4 5.4  0.8† 2.7  0.3
Note. Data represent the means  SEM for cardiac mitochondria isolated
from six individual rats receiving weekly injections for 7 consecutive weeks.
Oxidative phosphorylation was measured polarographically at 25°C in a total
volume of 1 ml. Respiration medium and other experimental details are given
under Experimental Procedure. State 3 and state 4 respiration rates, RCR, and
ADP/O were calculated as described under Experimental Procedure.
* p 	 0.05 compared to control.
† p 	 0.05 compared to doxorubicin-treated rats.
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Mitochondrial Ca2-Loading Capacity
Figure 1 illustrates the method employed for estimating
mitochondrial calcium loading capacity for both heart and
liver. Mitochondria were suspended in a medium containing
rotenone, oligomycin, calcium, and arsenazo III, which com-
plexes with free calcium to yield a blue color that is quantified
by spectrophotometry at 650 nm. Immediately upon addition of
succinate to energize the mitochondria, the absorbance of the
complex rapidly bleaches as the calcium is taken up into the
mitochondria. However, the absorbance subsequently begins to
increase as the intramitochondrial calcium concentration in-
creases to the point of triggering the mitochondrial permeabil-
ity transition, which releases the accumulated calcium back to
the extramitochondreal medium to complex once again with
the arsenazo dye. Calcium loading capacity is defined as the
maximum amount of calcium accumulated by the mitochon-
drial suspensions before inducing the permeability transition
and is expressed as nmol calcium/mg mitochondrial protein.
Performed under comparable conditions, the calcium load-
ing capacity was four- to five-fold greater for cardiac mito-
chondria than for liver (Table 4). Treatment of rats with DXR,
but not carvedilol, caused a significant reduction in the calcium
loading capacity of both heart and liver mitochondria. The
decrease in calcium loading capacity for liver mitochondria
was only 10%, whereas DXR treatment reduced mitochondrial
calcium loading capacity by nearly 50% for heart. Interest-
ingly, although cotreatment with carvedilol protected cardiac
mitochondria from DXR-induced decrease in calcium loading
capacity, carvedilol did not prevent the effect on liver mito-
chondria. Conversely, adding cyclosporin A, a potent and
specific inhibitor of the mitochondrial permeability transition
(Broekemeier et al., 1989), to the reaction medium in vitro
restored mitochondrial calcium loading capacity for both heart
and liver to values greater than that observed for saline-injected
controls. This is consistent with cyclosporin preventing the
recycling of calcium across the inner membrane of cardiac
mitochondria (Solem and Wallace, 1993; Zhou et al., 2000).
Mitochondrial Electron Chain Enzyme Activities
A final indication of the effects of DXR and carvedilol
treatment in vivo on mitochondrial bioenergetics was to mea-
sure the specific activities of Complex I and Complex IV in
heart and liver mitochondria from treated rats (Table 5). Sub-
chronic treatment with DXR caused a significant (35%) inhi-
bition of cardiac mitochondrial Complex I activity, but the
activity of Complex IV was unaltered. Contrast this with the
effects of DXR in liver, where Complex IV, but not Complex
I, was inhibited by treatment with DXR in vivo. In both cases,
however, coadministration of carvedilol prevented the inhibi-
tory effect of DXR on mitochondrial respiratory enzyme ac-
tivity.
Histopathology
When examined by light and electron microscopy, cardio-
myocytes from carvedilol-injected rats exhibited normal mor-
TABLE 4
Heart and Liver Mitochondrial Ca2-Loading Capacity
Treatment
Heart
mitochondria
Liver
mitochondria
(nmol/mg protein)
Saline 695  145 144  12
Doxorubicin 379  143* 127  10*
Carvedilol 715  86 143  13
Doxorubicin/carvedilol 696  60† 124  5*
Doxorubicin  cyclosporine A 884  43† 154  9†
Note. Values are means SEM (n  6) for animals receiving seven weekly
injections of doxorubicin (2 mg/kg/week sc) and carvedilol (1 mg/kg/week ip).
* Statistically significant compared to control group (p 	 0.05).
† Statistically significant compared to doxorubicin group (p 	 0.05).
FIG. 1. Quantification of the mitochondrial calcium loading capacity.
Freshly isolated rat heart or liver mitochondria were suspended at 0.25 mg
protein/ml in a medium containing 130 mM sucrose, 50 mM KCl, 2.5 mM
KH2PO4, and 5 mM Hepes (pH 7.4), to which was added 2 M rotenone, 1
g/ml oligomycin, 100 M arsenazo III, and 40–200 nmol calcium. The
active accumulation of calcium by the mitochondria was initiated by adding 10
mM succinate and the absorbance monitored continuously for 15 min. The
traces are representative of several replications for each type of mitochondrial
preparation.
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phology and were indistinguishable from controls (Fig. 2A).
However, as reported previously (Zhou et al., 2000), grade I
cardiomyopathy occurred in all rats injected with doxorubicin,
as illustrated by the appearance of enlarged, swollen mitochon-
dria and vacuoles within the cytoplasm (Figs. 2B and 3A,
Table 6). Carvedilol appeared to have a significant cardiopro-
tective effect on cardiac myocytes of rats treated with doxoru-
bicin (Table 6). One of four rats in the doxorubicin  carve-
dilol treatment group was classified as grade 0 and three of four
were classified as grade 1, that is less than 5% of the myocytes
showed damage. Compared to doxorubicin treatment alone,
there were fewer damaged cells in the carvedilol  doxorubi-
cin-treated rats, and those cells that were damaged usually
contained fewer and smaller vacuoles (Fig. 2C). When exam-
ined by electron microscopy, this cardioprotection was appar-
ent by the fewer and less extensively swollen cardiac mito-
chondria with less distension of the t-tubules and sarcoplasmic
reticulum (Fig. 3B).
DISCUSSION
Several hypotheses have been advanced to explain the dose-
limiting cumulative and irreversible cardiotoxicity caused by
doxorubicin (Singal et al., 1987; Olson and Mushlin, 1990),
most of which involve the generation of reactive oxygen spe-
cies. An emerging hypothesis expands on this concept to
implicate free radical-mediated interference with mitochon-
drial bioenergetics and calcium regulation as being definitive in
the pathogenic process (Ferrero et al., 1976; Wallace, 2000).
Doxorubicin associates with cardiolipin of the inner mitochon-
drial membrane, in which is embedded Complex I of the
respiratory chain. It is Complex I that catalyzes the futile redox
cycling of the doxorubicin to liberate reactive oxygen free
radicals (Doroshow, 1983), which in turn alters the thiol-
dependent regulation of the mitochondrial permeability transi-
tion pore (Sokolove, 1988; Solem and Wallace, 1993). As a
result, doxorubicin stimulates the cyclosporine A-sensitive dis-
ruption of mitochondrial calcium homeostasis and bioenerget-
ics (Solem et al., 1994, 1996; Zhou et al., 2000), which among
other things leads to interference with calcium-dependent cell
signaling pathways (Zhou et al., 2001). Additional indications
of oxidative injury to mitochondria include membrane lipid
peroxidation (Mimnaugh et al., 1983, 1985), inhibition of
respiration and oxidative phosphorylation, decreased mito-
chondrial ATPase activity, and a net decrease in the redox state
of respiratory carriers (Demant and Jensen, 1983; Praet et al.,
1984; Praet and Ruysschaert, 1993; Ji and Mitchell, 1994).
In light of the implication of oxidative stress in the patho-
genic mechanism, a number of attempts have been made to
assess the value of antioxidants in protecting against doxoru-
bicin cardiomyopathy (Praet et al., 1988; Singal et al., 1997).
Recent research has revealed three potential therapeutic agents
effective in limiting the extent of DXR-induced cardiomyop-
athy, all of which are based on the antioxidant properties of the
candidate compound (Dorr, 1996). Dexrazoxane decreases
DXR-induced cardiotoxicity by chelating essential transition
metals required for the generation of oxygen free radicals
(Seifert et al., 1994; Imondi, 1998; Herman et al., 2000). The
fact that dexrazoxane reduces the toxicity but not the antineo-
plastic activity of DXR is evidence for two distinct mecha-
nisms. Cardioprotection has also been demonstrated for the
lipid-lowering drug probucol (Singal et al., 1995, 2000) and
the aminothiol amifostine (Herman et al., 2000), both of which
express potent oxygen radical scavenging and antioxidant ac-
tivity in vitro. In both instances, cardioprotection against DXR-
induced toxicity is ascribed to the antioxidant properties of the
drug (Dorr, 1996).
Carvedilol offers another example of a drug candidate that
offers promising protection against cardiac failure (Feuerstein
et al., 1992; Kramer and Weglicki, 1996). The drug has been
widely prescribed to improve left ventricular function as the
result of episodes of ischemia and infarction, neurohumoral
mediated cardiac hypertrophy, and dilated cardiomyopathy as-
sociated with long-term dialysis (Lahiri, 1996; Tepper, 2001;
Jagasia and Shivkumar, 2002; Ponicke et al., 2002; Yaoita et
al., 2002). More recently, carvedilol has been shown to im-
prove left ventricular function in rats administered DXR (Mat-
sui et al., 1999). Invariably, the effectiveness of carvedilol has
been ascribed to its potent antioxidant properties, which are not
shared by all -adrenergic antagonist drugs (#519; Feuerstein
et al., 1992, 1997, 1998; Yue et al., 1994; Kramer and Weg-
licki, 1996; Matsui et al., 1999; Lysko et al., 2000). Although
there is substantial evidence to implicate that the cardioprotec-
tion is due to the strong antioxidant properties of carvedilol, we
can only infer from these previous reports. It remains feasible
that cardioprotection was manisfested by the vascular effects of
this -adrenergic antagonist.
Although considered to be cardioselective, DXR elicits ad-
verse effects in other tissues (e.g., liver) as well. The drug
TABLE 5
Activities of Mitochondrial Chain Complexes I and IV
in Heart and Liver Mitochondria
Treatment
Heart Liver
Complex I
(nmol/mg/min)
Complex IV
(k/mg/min)
Complex I
(nmol/mg/min)
Complex IV
(k/mg/min)
Saline 7.0  0.9 264  24 0.56  0.03 162  10
Doxorubicin 4.5  0.6* 280  36 0.50  0.09 106  26*
Carvedilol 6.0  0.9 270  26 0.49  0.05 142  10
Doxorubicin 
carvedilol 7.1  1.0† 301  29 0.48  0.04 158  12†
Note. Enzyme activities were determined as described under Experimental
Procedure. Data represent  SEM for four independent mitochondrial prepa-
rations.
* Statistically significant compared to control, p 	 0.05.
† Statistically significant compared to doxorubicin-treated rats, p 	 0.05.
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distributes throughout the systemic circulation and the cardio-
toxicity does not appear to be due to a preferential accumula-
tion in the heart (Yesair et al., 1972). For example, heart and
liver mitochondria have comparable capacities to bind adria-
mycin in vitro (Cheneval et al., 1985). Rather than being a
pharmacokinetic phenomenon, the difference in susceptibility
may be due to the relatively low levels of superoxide dis-
mutase, catalase, and glutathione peroxidase in cardiac tissue
compared to liver (Doroshow et al., 1980) or because of the
vastly greater numbers of mitochondria and higher energy
FIG. 2. Light micrographs of cardiac myocytes (700, toluidine blue stain). (A) Control myocytes of normal morphology. (B) Myocytes from
doxorubicin-treated rats show extensive vacuolization (arrows). (C) Myocytes from rats treated with doxorubicin plus carvedilol exhibit less extensive
vacuolization, with smaller and more sparsely distributed vacuoles compared to B. Bar represents 9 m (A–C).
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requirements of the heart (Wallace, 1992, 2000; Wallace et al.,
1997). Alternatively, heart mitochondria possess an exogenous
NADH dehydrogenase that is not present in liver. This enzyme
shuttles unpaired electrons to doxorubicin to generate super-
oxide free radicals, which have been implicated in the delete-
rious effects of DXR on heart tissue (Gille and Nohl, 1997).
Carvedilol was recently shown to be a potent inhibitor of the
external NADH dehydrogenase in heart mitochondria (Oliveira
et al., 2000). Accordingly, inhibition of the endogenous NADH
dehydrogenase by carvedilol may prevent the enzyme-cata-
lyzed generation of oxygen free radicals, which supposedly
mediate the oxidative injury to the cardiac mitochondria.
Carvedilol has also been shown to possess potent oxygen free
radical scavenging activity (Kramer and Weglicki, 1996),
which may contribute to the preservation of cardiac tissue
structure, mitochondrial bioenergetics, and contractile perfor-
mance in response to clinically limiting doses of doxorubicin.
Mitochondria isolated from DXR-treated rats exhibited a
marked dose-dependent reduction of oxygen consumption and
calcium loading capacity, whereas oxidative phosphorylation
(ADP/O ratio) remained unchanged. Inhibition of state 3 res-
piration in cardiac mitochondria isolated from rats treated
subchronically with DXR agrees with previous reports con-
cerning the acute toxicity of DXR (Bachmann and Zbinden,
1979). Whether this reflects the inhibition of complex I of the
respiratory chain or an induction of the permeability transition
and uncoupling of oxidative phosphorylation remain to be
determined. Regardless, the drug-dependent decrease in RCR
suggests that DXR interferes with the fundamental regulation
of oxidative phosphorylation in both cardiac and hepatic mi-
tochondria. The fact that carvedilol prevented the DXR-in-
duced interference with mitochondrial bioenergetics suggests
that, regardless of the underlying cause, the protective effect of
carvedilol is quite possibly at the level of preserving the redox
status of critical mitochondrial elements.
In conclusion, DXR-induced cardiomyopathy is mediated by
free radicals generated on the mitochondrial membranes, either
by the NADH dehydrogenase or Complex I of the respiratory
chain. Regardless of the source, the free radicals oxidize key
structural elements to interfere with mitochondrial bioenerget-
ics, which is a root cause for the contractile failure associated
with DXR cardiomyopathy. Carvedilol, because of its potent
antioxidant properties, offers a new therapeutic strategy, tar-
geted specifically at the myocardium, in limiting the extent of
cardiomyopathy associated with cumulative DXR therapy.
Carvedilol may be of particular advantage over current thera-
pies in that it belongs to the class of -adrenergic antagonists
that are widely prescribed as being of essential benefit in the
management of cardiogenic disorders, including drug-induced
congestive heart failure (Lahiri, 1996; Foody et al., 2002).
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FIG. 3. Representative electron micrographs of cardiac myocytes. (A)
Myocytes from doxorubicin treated rats showing large vacuoles and damaged
mitochondrial structures (arrows). (B) Myocytes from rats treated with doxo-
rubicin plus carvedilol showing smaller vacuoles with no damage to the
mitochondrial structures. Bar represents 1 m (A) and 1.4 m (B).
TABLE 6
Histopathological Grading and Cardiomyocyte Damage in Rats
Treated with Doxorubicin and/or Carvedilol
Treatment Mean gradea Cell damage scoreb
Saline 0.00 0.00  0.00
Carvedilol 0.25 0.75  0.75
Doxorubicin 1.00 8.75  1.75
Doxorubicin  carvedilol 0.75 4.25  1.18*
a Mean grade is expressed on a scale of 0–3 as assessed independently by
two separate scorers.
b Cell damage score represents the mean  SEM number of damaged
myocytes in a 202,500 m2 area.
* Significantly different from doxorubicin treatment, p 	 0.05 (n  4).
225CARVEDILOL PROTECTS AGAINST DOXORUBICIN TOXICITY
REFERENCES
Bachmann, E., Weber E., and Zbinden, G. (1987). Effects of mitoxantrone and
doxorubicin on energy metabolism of the rat heart. Cancer Treat. Rep. 71,
361–366.
Bachmann, E., and Zbinden, G. (1979). Effect of doxorubicin and rubidazone
on respiratory function and Ca2 transport in rat heart mitochondria. Toxicol.
Lett. 3, 29–34.
Billingham, M. E., Mason, J. W., Bristow, M. R., and Daniels, J. R. (1978).
Anthracycline cardiomyopathy monitored by morphologic changes. Cancer
Treat. Rep. 62, 865–872.
Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-dye bind-
ing. Anal. Biochem. 72, 248–254.
Bristow, M. R., Minobe, W. A., Billingham, M. E., Marmor, J. B., Johnson,
G. A., Ishimoto, B. M., Sageman, W. S., and Daniels, J. R. (1981). Anthra-
cycline-associated cardiac and renal damage in rabbits: Evidence for medi-
ation by vasoactive substances. Lab. Invest. 45, 157–168.
Broekemeier, K. M., Dempsey, M. E., and Pfeiffer, D. R. (1989). Cyclosporin
A is a potent inhibitor of the inner membrane permeability transition in liver
mitochondria. J. Biol. Chem. 264, 7826–7830.
Cheneval, D., Muller, M., Toni, R., Ruetz, S., and Carafoli, E. (1985).
Adriamycin as a probe for the transversal distribution of cardiolipin in the
inner mitochondrial membrane. J. Biol. Chem. 260, 13003–13007.
Davies, K. J., and Doroshow, J. H. (1986). Redox cycling of anthracyclines by
cardiac mitochondria. I. Anthracycline radical formation by NADH dehy-
drogenase. J. Biol. Chem. 261, 3060–3067.
Demant, E. J., and Jensen, P. K. (1983). Destruction of phospholipids and
respiratory-chain activity in pig-heart submitochondrial particles induced by
an adriamycin-iron complex. Eur. J. Biochem. 132, 551–556.
Doroshow, J. H. (1983). Anthracycline antibiotic-stimulated superoxide, hy-
drogen peroxide, and hydroxyl radical production by NADH dehydroge-
nase. Cancer Res. 43, 4543–4551.
Doroshow, J. H., Locker, G. Y., and Myers, C. E. (1980). Enzymatic defenses
of the mouse heart against reactive oxygen metabolites: Alterations pro-
duced by doxorubicin. J. Clin. Invest. 65, 128–135.
Dorr, R. T. (1996). Cytoprotective agents for anthracyclines. Semin. Oncol.
23(Suppl. 8), 23–34.
Estabrook, R. W. (1967). Mitochondrial respiratory control and the polaro-
graphic measurement of ADP/O ratios. Methods Enzymol. 10, 41–47.
Ferrero, M. E., Ferrero, E., Gaja, G., and Bernelli-Zazzera, A. (1976). Adria-
mycin: Energy metabolism and mitochondrial oxidations in the heart of
treated rabbits. Biochem. Pharmacol. 25, 125–130.
Feuerstein, G., Liu, G. L., Yue, T. L., Cheng, H. Y., Hieble, J. P., Arch, J. R.,
Ruffolo, R. R., Jr., and Ma, X. L. (1998). Comparison of metoprolol and
carvedilol pharmacology and cardioprotection in rabbit ischemia and reper-
fusion model. Eur. J. Pharmacol. 351, 341–350.
Feuerstein, G. Z., Bril, A., and Ruffolo, R. R., Jr. (1997). Protective effects of
carvedilol in the myocardium. Am. J. Cardiol. 80, 41L–45L.
Feuerstein, G. Z., Hamburger, S. A., Smith III, E. F., Bril, A., and Ruffolo,
R. R., Jr. (1992). Myocardial protection with carvedilol. J Cardiovasc.
Pharmacol. 19(Suppl. 1), S138–S141.
Foody, J. M., Farrell, M. H., and Krumholz, H. M. (2002). -Blocker therapy
in heart failure: Scientific review. JAMA 287, 883–889.
Gille, L., and Nohl, H. (1997). Analyses of the molecular mechanism of
adriamycin-induced cardiotoxicity. Free Radical Biol. Med. 23, 775–782.
Henry, T. R., Solem, L. E., and Wallace, K. B. (1995). Channel-specific
induction of the cyclosporine A-sensitive mitochondrial permeability tran-
sition by menadione. J. Toxicol. Environ. Health 45, 489–504.
Herman, E. H., Zhang, J., Chadwick, D. P., and Ferrans, V. J. (2000).
Comparison of the protective effects of amifostine and dexrazoxane against
the toxicity of doxorubicin in spontaneously hypertensive rats. Cancer
Chemother. Pharmacol. 45, 329–334.
Imondi, A. R. (1998). Preclinical models of cardiac protection and testing for
effects of dexrazoxane on doxorubicin antitumor effects. Semin. Oncol.
25(Suppl. 10), 22–30.
Jagasia, D. H., and Shivkumar, K. (2002). Carvedilol reduced mortality and
morbidity caused by myocardial infarction in patients with left ventricular
dysfunction. ACP J. Club 136, 7.
Ji, L. L. and Mitchell, E. W. (1994). Effects of Adriamycin on heart mito-
chondrial function in rested and exercised rats. Biochem. Pharmacol. 47,
877–885.
Kamo, N., Muratsugu, M., Hongoh, R., and Kobatake, Y. (1979). Membrane
potential of mitochondria measured with an electrode sensitive to tetraphe-
nyl phosphonium and relationship between proton electrochemical potential
and phosphorylation potential in steady state. J. Membr. Biol. 49, 105–121.
Kramer, J. H., and Weglicki, W. B. (1996). A hydroxylated analog of the
beta-adrenoceptor antagonist, carvedilol, affords exceptional antioxidant
protection to postischemic rat hearts. Free Radical Biol. Med. 21, 813–825.
Lahiri, A. (1996). Neurohumoral mechanisms in congestive heart failure and
the role of drugs with multiple actions: A review of carvedilol. Am. J. Ther.
3, 237–247.
Lefrak, E. A., Pitha, J., Rosenheim, S., and Gottlieb, J. A. (1973). A clinico-
pathologic analysis of adriamycin cardiotoxicity. Cancer 32, 302–314.
Lysko, P. G., Webb, C. L., Gu, J. L., Ohlstein, E. H., Ruffolo, R. R., Jr., and
Yue, T. L. (2000). A comparison of carvedilol and metoprolol antioxidant
activities in vitro. J. Cardiovasc. Pharmacol. 36, 277–281.
Mailer, K., and Petering, D. H. (1976). Inhibition of oxidative phosphorylation
in tumor cells and mitochondria by daunomycin and adriamycin. Biochem.
Pharmacol. 25, 2085–2089.
Matsui, H., Morishima, I., Numaguchi, Y., Toki, Y., Okumura K., and Hay-
akawa, T. (1999). Protective effects of carvedilol against doxorubicin-
induced cardiomyopathy in rats. Life Sci. 65, 1265–1274.
Mimnaugh, E. G., Gram, T. E., and Trush, M. A. (1983). Stimulation of mouse
heart and liver microsomal lipid peroxidation by anthracycline anticancer
drugs: Characterization and effects of reactive oxygen scavengers. J. Phar-
macol. Exp. Ther. 226, 806–816.
Mimnaugh, E. G., Trush, M. A., Bhatnagar, M., and Gram, T. E. (1985).
Enhancement of reactive oxygen-dependent mitochondrial membrane lipid
peroxidation by the anticancer drug adriamycin. Biochem. Pharmacol. 34,
847–856.
Nicolay, K., Fok, J. J., Voorhout, W., Post, J. A., and de Kruijff, B. (1986).
Cytofluorescence detection of adriamycin-mitochondria interactions in iso-
lated, perfused rat heart. Biochim. Biophys. Acta 887, 35–41.
Oliveira, P. J., Santos, D. J., and Moreno, A. J. (2000). Carvedilol inhibits the
exogenous NADH dehydrogenase in rat heart mitochondria. Arch. Biochem.
Biophys. 374, 279–285.
Olson, R. D., Boerth, R. C., Gerber, J. G., and Nies, A. S. (1981). Mechanism
of adriamycin cardiotoxicity: Evidence for oxidative stress. Life Sci. 29,
1393–1401.
Olson, R. D., and Mushlin, P. S. (1990). Doxorubicin cardiotoxicity: Analysis
of prevailing hypotheses [see comments]. FASEB J 4, 3076–3086.
Ponicke, K., Heinroth-Hoffmann, I., and Brodde, O. E. (2002). Differential
effects of bucindolol and carvedilol on noradenaline-induced hypertrophic
response in ventricular cardiomyocytes of adult rats. J. Pharmacol. Exp.
Ther. 301, 71–76.
Powis, G. (1989). Free radical formation by antitumor quinones. Free Radical
Biol. Med. 6, 63–101.
Praet, M., Calderon, P. B., Pollakis, G., Roberfroid, M., and Ruysschaert, J. M.
226 SANTOS ET AL.
(1988). A new class of free radical scavengers reducing adriamycin mito-
chondrial toxicity. Biochem. Pharmacol. 37, 4617–4622.
Praet, M., Pollakis, G., Goormaghtigh, E., and Ruysschaert, J. M. (1984).
Damages of the mitochondrial membrane in Adriamycin treated mice.
Cancer Lett. 25, 89–96.
Praet, M., and Ruysschaert, J. M. (1993). In-vivo and in-vitro mitochondrial
membrane damages induced in mice by adriamycin and derivatives. Bio-
chim. Biophys. Acta 1149, 79–85.
Ruffolo, R. R., Jr., Nichols, A. J., Stadel, J. M., and Hieble, J. P. (1991). Structure
and function of alpha-adrenoceptors. Pharmacol. Rev. 43, 475–505.
Seifert, C. F., Nesser, M. E., and Thompson, D. F. (1994). Dexrazoxane in the
prevention of doxorubicin-induced cardiotoxicity. Ann. Pharmacother. 28,
1063–1072.
Singal, P. K., Deally, C. M., and Weinberg, L. E. (1987). Subcellular effects
of adriamycin in the heart: A concise review. J. Mol. Cell. Cardiol. 19,
817–828.
Singal, P. K., and Iliskovic, N. (1998). Doxorubicin-induced cardiomyopathy
[see comments]. N. Engl. J. Med. 339, 900–905.
Singal, P. K., Iliskovic, N., Li, T., and Kumar, D. (1997). Adriamycin cardio-
myopathy: Pathophysiology and prevention. FASEB J 11, 931–936.
Singal, P. K., Li, T., Kumar, D., Danelisen, I., and Iliskovic, N. (2000).
Adriamycin-induced heart failure: Mechanism and modulation. Mol. Cell.
Biochem. 207, 77–86.
Singal, P. K., Siveski-Iliskovic, N., Hill, M., Thomas, T. P., and Li, T. (1995).
Combination therapy with probucol prevents adriamycin-induced cardiomy-
opathy. J. Mol. Cell. Cardiol. 27, 1055–1063.
Siveski-Iliskovic, N., Hill, M., Chow, D. A., and Singal, P. K. (1995). Probucol
protects against adriamycin cardiomyopathy without interfering with its
antitumor effect. Circulation 91, 10–15.
Sokolove, P. M. (1988). Mitochondrial sulfhydryl group modification by
adriamycin aglycones. FEBS Lett. 234, 199–202.
Solem, L. E., Heller, L. J., and Wallace, K. B. (1996). Dose-dependent increase
in sensitivity to calcium-induced mitochondrial dysfunction and cardiomy-
ocyte cell injury by doxorubicin. J. Mol. Cell. Cardiol. 28, 1023–1032.
Solem, L. E., Henry, T. R., and Wallace, K. B. (1994). Disruption of mito-
chondrial calcium homeostasis following chronic doxorubicin administra-
tion. Toxicol. Appl. Pharmacol. 129, 214–222.
Solem, L. E., and Wallace, K. B. (1993). Selective activation of the sodium-
independent, cyclosporin A-sensitive calcium pore of cardiac mitochondria
by doxorubicin. Toxicol. Appl. Pharmacol. 121, 50–57.
Tadolini, B., and Franconi, F. (1998). Carvedilol inhibition of lipid peroxida-
tion: A new antioxidative mechanism. Free Radical Res. 29, 377–387.
Taylor, R. W., Birch-Machin, M. A., Bartlett, K., and Turnbull, D. M. (1993).
Succinatecytochrome c reductase: Assessment of its value in the investiga-
tion of defects of the respiratory chain. Biochim. Biophys. Acta 1181,
261–265.
Tepper, D. (2001). Frontiers in congestive heart failure: Dilated cardiomyop-
athy in dialysis patients—beneficial effects of carvedilol: A double-blind,
placebo-controlled trial. Congest. Heart Fail. 7, 170.
Trounce, I. A., Kim, Y. L., Jun, A. S., and Wallace, D. C. (1996). Assessment
of mitochondrial oxidative phosphorylation in patient muscle biopsies, lym-
phoblasts, and transmitochondrial cell lines. Methods Enzymol. 264, 484–
509.
Wallace, D. C. (1992). Diseases of the mitochondrial DNA. Annu. Rev.
Biochem. 61, 1175–1212.
Wallace, K. B. (2001). Doxorubicin-induced mitochondrial cardiomyopathy.
In Mitochondria in Pathogenesis. (J. J. Lemasters and A.-L. Nieminen,
Eds.), Chapt. 25, pp. 467–488. Kluwer Academic/Plenum Publishers, New
York.
Wallace, K. B., Eells, J. T., Madeira, V. M., Cortopassi, G. and Jones, D. P.
(1997). Mitochondria-mediated cell injury: Symposium overview. Fundam.
Appl. Toxicol. 38, 23–37.
Yaoita, H., Sakabe, A., Maehara, K. and Maruyama, Y. (2002). Different
effects of carvedilol, metoprolol, and propranolol on left ventricular remod-
eling after coronary stenosis or after permanent coronary occlusion in rats.
Circulation 105, 975–980.
Yesair, D. W., Schwartzbach, E., Shuck, D., Denine, E. P., and Asbell, M. A.
(1972). Comparative pharmacokinetics of daunomycin and adriamycin in
several animal species. Cancer Res. 32, 1177–1183.
Yue, T. L., Cheng, H. Y., Lysko, P. G., McKenna, P. J., Feuerstein, R., Gu,
J. L., Lysko, K. A., Davis, L. L., and Feuerstein, G. (1992a). Carvedilol, a
new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free
radical scavenger. J. Pharmacol. Exp. Ther. 263, 92–98.
Yue, T. L., McKenna, P. J., Gu, J. L., Cheng, H. Y., Ruffolo, R. E., Jr., and
Feuerstein, G. Z. (1994). Carvedilol, a new vasodilating beta adrenoceptor
blocker antihypertensive drug, protects endothelial cells from damage ini-
tiated by xanthine-xanthine oxidase and neutrophils. Cardiovasc. Res. 28,
400–406.
Yue, T. L., McKenna, P. J., Ruffolo, R. R., Jr., and Feuerstein, G. (1992b).
Carvedilol, a new beta-adrenoceptor antagonist and vasodilator antihyper-
tensive drug, inhibits superoxide release from human neutrophils. Eur.
J. Pharmacol. 214, 277–280.
Zhou, S., Heller, L. J., and Wallace, K. B. (2001). Interference with calcium-
dependent mitochondrial bioenergetics in cardiac myocytes isolated from
doxorubicin-treated rats. Toxicol. Appl. Pharmacol. 175, 60–67.
Zhou, S., Starkov, A., Froberg, M. K., Leino, R. L., and Wallace, K. B. (2001).
Cumulative and irreversible cardiac mitochondrial dysfunction induced by
doxorubicin. Cancer Res. 61, 771–777.
227CARVEDILOL PROTECTS AGAINST DOXORUBICIN TOXICITY
